news10 Nov 2022 14:50
NanoString Technologies (NASDAQ:NSTG) and Abcam (NASDAQ:ABCM) said they expanded their collaboration to advance spatial multiomics research.
Under the agreement, the companies will co-market Abcam antibodies for NanoString's high-plex spatial multiomic solutions.
Abcam RabMAb recombinant antibodies will be commercialized as part of the first 64-plex protein panel for NanoString's CosMx Spatial Molecular Imager (SMI).
"This relationship will further expand the depth and breadth of spatial biology offerings on NanoString instrumentation into new frontiers of human biology down to single-cell resolution— a true revolution in the spatial biology field," said NanoString President and CEO Brad Gray.